Suchergebnisse - "Stilgenbauer, Stephan"

PubPharm (682)

1

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

enthalten in: Blood advances | 2024

von Stilgenbauer, S. | Tausch, E. | Roberts, A. | +19

2

Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL : Final efficacy and ctDNA analysis of the CLL2-BAAG trial

enthalten in: Blood | 2024

von Fürstenau, M. | Giza, A. | Weiss, J. | +22

3

Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies

enthalten in: Blood | 2024

von Langerbeins, P. | Giza, A. | Robrecht, S. | +21

4

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG) : Final analysis of a multicenter, open-label phase-II-trial

enthalten in: American journal of hematology | 2024

von Cramer, P. | von Tresckow, J. | Fink, A. | +15

5

Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms – a practical guide to WHO HAEM5

enthalten in: Medizinische Genetik | 2024

von Tausch, E. | López, C. | Stilgenbauer, S. | +1

6

Venetoclax Initiation in Chronic Lymphocytic Leukemia : International Insights and Innovative Approaches for Optimal Patient Care

enthalten in: Cancers | 2024

von Anderson, M. | Walewska, R. | Hackett, F. | +8

7

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma : Results From the European Mantle Cell Lymphoma Elderly Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Hoster, E. | Delfau-Larue, M. | Macintyre, E. | +15

8

Tislelizumab plus zanubrutinib for Richter transformation : the phase 2 RT1 trial

enthalten in: Nature medicine | 2024

von Al-Sawaf, O. | Ligtvoet, R. | Robrecht, S. | +20

9

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

enthalten in: Leukemia & lymphoma | 2024

von Hess, G. | Dreyling, M. | Oberic, L. | +22

10

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma - a randomized, open-label phase III trial of the European mantle cell lymphoma network

enthalten in: ResearchSquare.com | 2023

von Fischer, L. | Jiang, L. | Dürig, J. | +28

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[69]